DUBLIN, Ireland -- Elan Corp. plc continues to rattle investor nerves, with bad news from the clinic following sharply on the heels of bad news from the boardroom.
Last week, the Dublin-based company and its partner, Cambridge, Mass.-based Biogen Inc., disclosed the failure of their anti-inflammatory drug Antegren (natalizumab) to meet the primary endpoint of a Phase III induction trial in Crohn's disease.
A total of 905 patients participated in the double-blind, placebo-controlled study. The primary endpoints were response, defined as a reduction of at least 70 points in the Crohn's Disease Activity Index at week 10, and remission, defined as a CDAI score of less than or equal to 150, …
No comments:
Post a Comment